Manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma
In this MEDtalk, Jean Marie Michot, MD, Paris, presents insights from poster S216 at EHA22, where a Cereblon E3 Ligase Modulator agent in monotherapy demostrate a showed a manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
